<\/p>\n
Amerikan Kanser Kongresinde payla\u015f\u0131lan bilimsel \u00e7al\u0131\u015fmayla k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanserlerinde<\/strong> uygulanan ak\u0131ll\u0131 tedavi y\u00f6nteminin<\/strong> hastal\u0131\u011f\u0131n tekrarlama riskini y\u00fczde 27 oran\u0131nda azaltt\u0131\u011f\u0131 ortaya konuldu.<\/p>\n D\u00fcnya Aferez Birli\u011fi Ba\u015fkan\u0131 Prof. Dr. Fevzi Altunta\u015f, bas\u0131n mensuplar\u0131yla bir araya gelerek 31 May\u0131s-4 Haziran’da \u015eikago’da d\u00fczenlenen Amerikan Kanser Kongresinde (ASCO2024<\/strong>) payla\u015f\u0131lan yeni geli\u015fmelere ili\u015fkin de\u011ferlendirmelerde bulundu.<\/p>\n Kongrenin ana temas\u0131n\u0131n bu sene “kanser y\u00f6netimi” oldu\u011funu ifade eden Altunta\u015f, “Art\u0131k \u00f6n\u00fcm\u00fczdeki s\u00fcre\u00e7te sadece kanser tedavisi de\u011fil, kanser y\u00f6netimine odaklanmal\u0131y\u0131z. Hastan\u0131n, hastal\u0131\u011f\u0131n \u00f6nlenmesinden yas dan\u0131\u015fmanl\u0131\u011f\u0131na kadar b\u00fct\u00fcn bir s\u00fcrecinin her a\u015famas\u0131n\u0131 geli\u015ftirmeliyiz.” diye konu\u015ftu.<\/p>\n Sa\u011fl\u0131k alan\u0131nda klinik ara\u015ft\u0131rmalara kat\u0131lmak ve bunu te\u015fvik etmek gerekti\u011fini dile getiren Altunta\u015f, kongrede kanserle m\u00fccadelede yeni bir ilaca dair geli\u015fmelerin de konu\u015fuldu\u011funu aktard\u0131.<\/p>\n D\u00fcnyan\u0131n kanser tedavisinde farkl\u0131 noktaya gitti\u011fine dikkati \u00e7eken Altunta\u015f, “\u00d6n\u00fcm\u00fczdeki s\u00fcre\u00e7te bunun klinik yans\u0131malar\u0131n\u0131 g\u00f6rece\u011fiz.” dedi.<\/p>\n Kongrede lenfoma kanserinin tedavisine ili\u015fkin yeni geli\u015fmelerin de ele al\u0131nd\u0131\u011f\u0131n\u0131 belirten Altunta\u015f, yenilik\u00e7i tedavilerle ba\u015far\u0131 oran\u0131n\u0131n y\u00fczde 80’lere kadar \u00e7\u0131kt\u0131\u011f\u0131n\u0131 vurgulad\u0131.<\/p>\n Altunta\u015f, “Kanser hastalar\u0131n\u0131n ya\u015fam s\u00fcreleri uzamakta, ya\u015fam kaliteleri her ge\u00e7en g\u00fcn artmaktad\u0131r. L\u00f6semi, lenfoma gibi hematolojik kanserlerde ba\u015far\u0131 oranlar\u0131 artm\u0131\u015ft\u0131r.” diye konu\u015ftu.<\/p>\n Ankara Hematoloji ve Onkoloji Derne\u011fi Genel Sekreteri Do\u00e7. Dr. Cengiz Kara\u00e7in de kongrede akci\u011fer kanseri tedavisine y\u00f6nelik “ADRIATIC” isimli bilimsel \u00e7al\u0131\u015fman\u0131n sonu\u00e7lar\u0131n\u0131n payla\u015f\u0131ld\u0131\u011f\u0131 bilgisini verdi.<\/p>\n K\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanserli hastalara y\u00f6nelik yakla\u015f\u0131k 20 y\u0131ld\u0131r herhangi bir yeni geli\u015fmenin ya\u015fanmad\u0131\u011f\u0131na i\u015faret eden Kara\u00e7in, \u015funlar\u0131 kaydetti:<\/p>\n “\u00c7ok \u00e7al\u0131\u015fma yap\u0131l\u0131yordu ama pozitif sonu\u00e7lanan \u00e7al\u0131\u015fma yoktu, ta ki bu y\u0131lki ASCO’daki \u00e7al\u0131\u015fma a\u00e7\u0131klanana kadar. ADRIATIC \u00e7al\u0131\u015fmas\u0131nda, k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanserli hastalarda g\u00fcn\u00fcm\u00fcz standartlar\u0131nda ‘kemoradyoterapi’ dedi\u011fimiz kemoterapiyle \u0131\u015f\u0131n tedavisini birlikte uyguluyoruz. Bu \u00e7al\u0131\u015fma, ‘Bu tedavi tamamland\u0131ktan sonra ak\u0131ll\u0131 tedavi gibi imm\u00fcnoterapinin, hastal\u0131\u011f\u0131n tekrarlamas\u0131n\u0131 \u00f6nlemede bir faydas\u0131 var m\u0131?’ sorusuna cevap arad\u0131. Bu ilac\u0131n uygulanmas\u0131 bu riski y\u00fczde 27 oran\u0131nda azaltt\u0131. \u0130statistiksel anlamda da klinik anlamda da anlaml\u0131yd\u0131. Bu geli\u015fme hem hastalar\u0131m\u0131z hem bizler i\u00e7in son 20 y\u0131lda ilk pozitif sunulmu\u015f \u00e7al\u0131\u015fma olarak hepimizin y\u00fcz\u00fcn\u00fc g\u00fcld\u00fcrd\u00fc.”<\/p>\n\u0130mm\u00fcnoterapinin akci\u011fer kanseri tekrarlama riskini azaltt\u0131\u011f\u0131 belirlendi<\/h3>\n